Doctors frequently monitor prostate cancer with a blood test called prostate-specific antigen (PSA). When treatment is effective, PSA levels typically decrease, but clinicians need clear targets to determine if a patient is responding adequately. A recent extensive real-world study has revealed that a PSA level dropping below 0.2 nanograms per milliliter within nine months of starting treatment can be especially meaningful for men with prostate cancer that has spread beyond the prostate. Men whose PSA levels fell under this threshold experienced significantly better survival rates.
The study was published online in CANCER, a peer-reviewed journal of the American Cancer Society. It analyzed health records from the U.S. Veterans Health Administration, involving 4,890 patients treated between 2018 and 2023. These individuals had metastatic hormone-sensitive prostate cancer, meaning the cancer had spread but still responded to therapies that suppress or block testosterone. Since testosterone can promote prostate cancer growth, standard care often involves androgen deprivation therapy, which significantly reduces male hormone levels or inhibits their effects on cancer cells. Many doctors also combine this with additional medications to better control the disease. Despite modern treatments, patient responses vary widely, making early indicators of treatment effectiveness particularly valuable.
PSA is a protein produced by the prostate gland, including prostate cancer cells. A decline in PSA levels after treatment generally indicates a reduction in cancer activity, but there has been ongoing debate about which specific responses best predict long-term outcomes. Previous clinical trials suggested that reaching a PSA level below 0.2 ng/mL was strongly associated with improved survival. In practice, clinicians often consider the percentage decrease in PSA, such as a 90% reduction, as another marker of response.
In this large observational study, researchers tracked patients over a median period of around two years, during which 896 patients passed away. The findings showed that the most significant predictor of improved survival was the PSA level actually achieved. Men whose PSA dropped below 0.2 ng/mL within nine months were 54% less likely to die compared to those whose PSA did not reach that level. Interestingly, the extent of the PSA decline—such as a reduction of 90%—did not provide the same prognostic information. Patients who experienced large percentage drops but still maintained PSA levels above 0.2 ng/mL did not show improved survival, implying that the final PSA target might be more crucial than the magnitude of decline along the way.
The study also indicated that patients receiving a combination of testosterone-lowering therapy and additional drugs that further block testosterone were more likely to reach the very low PSA goal. This supports the trend toward more intensive combination treatments for suitable patients with metastatic prostate cancer.
Dr. Stephen J. Freedland, a urology professor at Cedars-Sinai and a physician at Durham VA Medical Center, commented that these findings endorse aiming for a PSA level below 0.2 ng/mL as a treatment goal. Patients who do not reach this level might require closer monitoring or consideration of more aggressive treatment options.
A significant strength of the research is that it examined a large number of patients receiving routine medical care, demonstrating that real-world results align with those seen in clinical trials. However, it’s important to recognize that these findings do not necessarily prove that lowering PSA below 0.2 ng/mL will automatically extend life for every individual. This was an observational study, and often, patients who reach very low PSA levels may have cancers that are inherently more sensitive to treatment.
Ultimately, the evidence suggests that a PSA level below 0.2 ng/mL within nine months serves as a strong marker of both treatment effectiveness and positive prognosis. Future research should explore whether adjusting therapies early for patients who do not meet this target could actually improve survival rates.
For patients and healthcare providers, this study offers a straightforward, practical benchmark. Achieving a very low PSA early on may identify individuals performing particularly well, while not reaching this goal could prompt a re-evaluation of the current treatment plan.















